Emergent BioSolutions reported strong Q3 2024 results with total revenues of $293.8 million, up 9% YoY, and net income of $114.8 million, a 144% increase YoY. Adjusted EBITDA surged 432% to $105.3 million, while segment gross margin improved to 57% from 33% last year.The company strengthened its financial position through strategic initiatives, including securing a new $250 million term loan, a $100 million asset-backed loan facility, and generating $117 million from asset sales. Notable transactions included the $75 million sale of RSDL product to SERB Pharmaceuticals and the $35 million sale of the Baltimore-Camden manufacturing site.Based on strong performance, Emergent raised its FY 2024 guidance, projecting total revenues of $1,065-$1,125 million and adjusted EBITDA of $180-$200 million. The company's transformation plan is progressing well, focusing on profitable growth and operational improvements in its core medical countermeasures and NARCAN Nasal Spray businesses.

Emergent BioSolutions reported strong Q3 2024 results with total revenues of $293.8 million, up 9% YoY, and net income of $114.8 million, a 144% increase YoY. Adjusted EBITDA surged 432% to $105.3 million, while segment gross margin improved to 57% from 33% last year.The company strengthened its financial position through strategic initiatives, including securing a new $250 million term loan, a $100 million asset-backed loan facility, and generating $117 million from asset sales. Notable transactions included the $75 million sale of RSDL product to SERB Pharmaceuticals and the $35 million sale of the Baltimore-Camden manufacturing site.Based on strong performance, Emergent raised its FY 2024 guidance, projecting total revenues of $1,065-$1,125 million and adjusted EBITDA of $180-$200 million. The company's transformation plan is progressing well, focusing on profitable growth and operational improvements in its core medical countermeasures and NARCAN Nasal Spray businesses.